ARID2 and hepatocellular carcinoma: The ARID2 mutations, which seemed enriched in HCV-associated HCC in the US and European patient populations (14%, 6 out of 43 tumors) compared with the overall mutation frequency (6.5%, 9 out of 139 tumors), attracted much interest.